Yarrow Bioscience(NASDAQ) YARW

Market Cap$175.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-97%
1 Year+79%
1 Month-31%
$19.33
+3.93%
+0.73Today
After hours$19.03-$0.30 (-1.55%)
Yarrow Bioscience last closing stock price
MetricPriceDate
Last closeUSD 18.602026-10-13
Yarrow Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.69%USD 18.732026-10-06
1 month-31.14%USD 27.012026-09-11
3 month-12.92%USD 21.362026-07-15
Year to date+13.66%USD 16.362025-12-31
1 year+78.97%USD 10.392025-10-13
3 year-76.02%USD 77.582023-10-13
5 year-97.12%USD 644.882021-10-14
Since inception-99.76%USD 7,636.972020-03-10

Yarrow Bioscience Financials at a Glance

Market Cap

$175.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$482.00K

Net Income (TTM)

-$18.71M

EPS (TTM)

-$23.46

P/E Ratio

-0.79

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$19.33

Volume

105,461.245

Open

$18.56

Previous Close

$18.90

Daily Range

$18.16 - $19.66

52-Week Range

$9.05 - $44.28

Estimated Earnings Date

Nov 5, 2026

YARW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yarrow Bioscience

Yarrow Bioscience Inc is a clinical-stage biotechnology company dedicated to developing innovative therapies for autoimmune thyroid diseases. The company's lead product candidate, YB-101, aims to be a first-in-class monoclonal antibody targeting the thyroid stimulating hormone receptor, potentially transforming treatment for Graves' disease and thyroid eye disease.

Products and Services
  • YB-101: A monoclonal antibody targeting TSHR
  • Research and development focused on autoimmune thyroid diseases
  • Potential therapies for Graves' disease and thyroid eye disease
Growth Outlook
  • Significant market potential in autoimmune thyroid disease treatments
  • Strong pipeline with ongoing clinical trials for YB-101
  • Increasing awareness and diagnosis of thyroid-related conditions
Financial Highlights
  • Q2 2026 revenue of $97,000, up from $86,000 in Q1 2026
  • Cash and cash equivalents of $22.9 million as of June 30, 2026
  • Trailing twelve months gross profit margin at 97.5%
Yarrow Bioscience Inc is positioned in a growing sector with a focus on autoimmune thyroid diseases, an area with significant unmet medical needs. The lead product candidate, YB-101, represents a promising advancement in treatment options, potentially addressing the root causes of these conditions. The company has demonstrated a commitment to research and development, as evidenced by its substantial investment in R&D expenses, which totaled $788,000 in Q2 2026. Financially, Yarrow has maintained a strong cash position, with $22.9 million in cash and cash equivalents, providing a solid foundation for ongoing clinical trials and operational needs. The recent revenue growth from $86,000 in Q1 to $97,000 in Q2 indicates a positive trend, reflecting the company's potential to scale its operations as it advances its product pipeline. Overall, Yarrow Bioscience Inc presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in innovative therapies for autoimmune diseases. The company's strategic focus on a niche market, combined with its robust financial position, positions it well for future growth and development.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

10

CEO

Rebecca Velez Frey, PharmD

Website

www.yarrowbioscience.com

Headquarters

New Haven, CT 06513, US

YARW Financials

Key Financial Metrics (TTM)

Gross Margin

97.51%

Operating Margin

-4134.65%

Net Income Margin

-3881.54%

Return on Equity

-70.23%

Return on Capital

-107.15%

Return on Assets

-79.26%

Earnings Yield

-1.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$175.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.44M

Volume

105.46K

Avg. Volume

87.16K

Financials (TTM)

Gross Profit

$470.00K

Operating Income

-$19.93M

EBITDA

-$18.84M

Operating Cash Flow

-$16.93M

Capital Expenditure

$0.00

Free Cash Flow

-$16.93M

Cash & ST Invst.

$22.93M

Total Debt

$0.00

Yarrow Bioscience Performance Analysis

Yarrow Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 477,000-48.8%
20232023-12-31USD 424,000-11.1%
20242024-12-31USD 501,00018.2%
20252025-12-31USD 570,00013.8%
Yarrow Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30144.9%
Q42025-12-31-23.1%
Q12026-03-31-33.8%
Q22026-06-3012.8%
Yarrow Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.34-99.1%
20232023-12-31USD -138.481121.2%
20242024-12-31USD -46.77-66.2%
20252025-12-31USD -30.96-33.8%
Yarrow Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-26.3%
Q42025-12-3114.6%
Q12026-03-3142.3%
Q22026-06-3016.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$97.00K

+40.6%

Gross Profit

$91.00K

+31.9%

Gross Margin

93.81%

N/A

Market Cap

$175.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$17.55M

N/A

Employees

10

N/A

Net Income

-$3.01M

+47.7%

EBITDA

-$2.89M

+49.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$22.93M

-42.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-79.26%

N/A

Return on Invested Capital

-90.33%

N/A

Free Cash Flow

-$1.99M

+81.6%

Operating Cash Flow

-$1.99M

+81.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KTTAPasithea Therapeutics Corp.
$0.41-3.40%
BCLIBrainstorm Cell Therapeutics Inc.
$0.84+0.41%
ENSCEnsysce Biosciences, Inc.
$0.57-0.68%
QNRXQuoin Pharmaceuticals, Ltd.
$4.10-1.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About YARW

What is the current price of Yarrow Bioscience?

Yarrow Bioscience is trading at $18.90 per share.

What is the 52-week range for Yarrow Bioscience?

Over the past 52 weeks, Yarrow Bioscience has traded between $9.05 and $44.28.

How much debt does Yarrow Bioscience have?

As of the most recent reporting period, Yarrow Bioscience reported total debt of $0.00.

How much cash does Yarrow Bioscience have on hand?

Yarrow Bioscience reported $22.93M in cash and cash equivalents in its most recent financial results.

What is Yarrow Bioscience’s dividend yield?

Yarrow Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services